IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin

Pang, Nengzhi; Shi, Jingxuan; Qin, Le; Chen, Aiming; Tang, Yuou; Yang, Hainan; Huang, Yufeng; Wu, Qingde; Li, Xufeng; He, Bingjia; Li, Tianheng; Liang, Baoxia; Zhang, Jinglin; Cao, Bihui; Liu, Manting; Feng, Yunfei; Ye, Xiaodie; Chen, Xiaopei; Wang, Lu; Tian, Yu; Li, Hao; Li, Junping; Hu, Hong; He, Jingping; Hu, Yuling; Zhi, Cheng; Tang, Zhaoyang; Gong, Yibo; Xu, Fangting; Xu, Linfeng; Fan, Weijun; Zhao, Ming; Chen, Deji; Lian, Hui; Yang, Lili; Li, Peng; Zhang, Zhenfeng

doi:10.1186/s13045-021-01128-9

Public

IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin

Published in Journal of Hematology & Oncology • Jul 29, 2021

Authors:

Nengzhi Pang

Jingxuan Shi

Le Qin

Abstract

Although chimeric antigen receptor (CAR)-engineered T cells have shown great success in the treatment of B cell malignancies, this strategy has limited efficacy in patients with solid tumors. In mouse CAR-T cells, IL-7 and CCL19 expression have been demonstrated to improve T cell infiltration and CA...

Subject

Mesothelin

Glypican 3

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!